

(12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(19) World Intellectual Property
Organization
International Bureau

(43) International Publication Date
04 May 2023 (04.05.2023)



(10) International Publication Number
WO 2023/072913 A1

(51) International Patent Classification:

C07D 239/70 (2006.01) A61K 31/506 (2006.01)
C07D 401/04 (2006.01) A61K 31/537 (2006.01)
C07D 403/04 (2006.01) A61K 31/5377 (2006.01)
C07D 405/12 (2006.01) A61K 31/538 (2006.01)
C07D 498/02 (2006.01) A61P 35/00 (2006.01)

(21) International Application Number:

PCT/EP2022/079738

(22) International Filing Date:

25 October 2022 (25.10.2022)

(25) Filing Language:

English

(26) Publication Language:

English

(30) Priority Data:

21204520.7 25 October 2021 (25.10.2021) EP
22167146.4 07 April 2022 (07.04.2022) EP
22186200.6 21 July 2022 (21.07.2022) EP

(71) Applicant: **TWENTYEIGHT-SEVEN, INC.** [US/US];
490 Arsenal Way, Suite 100B, Watertown, Massachusetts
02472 (US).

(72) Inventors: **WEILER, Sven**; c/o Basilea Pharmaceutica
International AG, Allschwil, Hegenheimermattweg 167b,
4123 Allschwil (CH). **GAUCHER, Bérangère**; Basilea
Pharmaceutica International AG, Allschwil, Hegenheim-
ermattweg 167b, 4123 Allschwil (CH). **RICHALET, Flo-
rian**; Basilea Pharmaceutica International AG, Allschwil,
Hegenheimermattweg 167b, 4123 Allschwil (CH).
RADIMERSKI, Thomas; c/o Basilea Pharmaceutica In-
ternational AG, Allschwil, Hegenheimermattweg 167b,
4123 Allschwil (CH). **ALOIA, Andrea**; Basilea Pharma-
ceutica International AG, Allschwil, Hegenheimermattweg
167b, 4123 Allschwil (CH).

(81) Designated States (unless otherwise indicated, for every
kind of national protection available): AE, AG, AL, AM,
AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, BZ,
CA, CH, CL, CN, CO, CR, CU, CV, CZ, DE, DJ, DK, DM,
DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT,
HN, HR, HU, ID, IL, IN, IQ, IR, IS, IT, JM, JO, JP, KE,

KG, KH, KN, KP, KR, KW, KZ, LA, LC, LK, LR, LS, LU,
LY, MA, MD, MG, MK, MN, MW, MX, MY, MZ, NA, NG,
NI, NO, NZ, OM, PA, PE, PG, PH, PL, PT, QA, RO, RS,
RU, RW, SA, SC, SD, SE, SG, SK, SL, ST, SV, SY, TH,
TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, WS,
ZA, ZM, ZW.

(84) Designated States (unless otherwise indicated, for every
kind of regional protection available): ARIPO (BW, CV,
GH, GM, KE, LR, LS, MW, MZ, NA, RW, SD, SL, ST, SZ,
TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, RU,
TJ, TM), European (AL, AT, BE, BG, CH, CY, CZ, DE,
DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU,
LV, MC, ME, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI,
SK, SM, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN,
GQ, GW, KM, ML, MR, NE, SN, TD, TG).


Declarations under Rule 4.17:

— as to applicant's entitlement to apply for and be granted a
patent (Rule 4.17(ii))

Published:

— with international search report (Art. 21(3))
— in black and white; the international application as filed
contained color or greyscale and is available for download
from PATENTSCOPE

(54) Title: BENZO[H]QUINAZOLINE-4-AMINE DERIVATIVES FOR THE TREATMENT OF CANCER



(I)

(57) Abstract: The invention provides compounds of formula (I) (I) and phar-
maceutically acceptable salts thereof; wherein Ra and Rb are both -CH3 or Ra
and Rb together form a -CH2-CH2-CH2- or a -CH2-CH2-CH2-CH2-bridging
moiety; A is -CH2- or -C(=O)-; T is -N(R11)-, -N(R11)-C(=O)-, -N(R11)-S(O2)
-, -O-, -C(R12)(R13)-, -C=C(R12)2, -S-, -S(O)-, -S(O2)-, -S(O2)-N(R14)- or -
C(=O)-N(R14)-; and wherein R1, R2, R11, R12, R13 and R14 are as defined in
the claims, as well as methods of using the compounds for the treatment of neo-
plastic diseases such as cancer.

WO 2023/072913 A1